|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 684.36 Million
|
|
CAGR (2025-2030)
|
4.17%
|
|
Fastest Growing Segment
|
Cell Culture Systems & 3D Cell Culture
|
|
Largest Market
|
Northern & Central
|
|
Market Size (2030)
|
USD 864.48 Million
|
Market Overview
Saudi
Arabia Life Science Tools Market was valued at USD 684.36 Million in 2024 and
is expected to reach USD 864.48 Million by 2030 with a CAGR of 4.17% during the
forecast period.
The life science tools market in Saudi Arabia is experiencing
significant growth, driven by increasing investments in healthcare,
biotechnology, and pharmaceutical sectors. The Kingdom’s Vision 2030
initiative, aimed at diversifying the economy and reducing reliance on oil, has
played a key role in fostering the development of the life sciences industry. Government-backed
projects and strategic partnerships between public and private entities have
led to advancements in research and development (R&D), particularly in
fields such as genomics, proteomics, and molecular diagnostics.
One
of the prominent factors contributing to the expansion of the life science
tools market is the rising demand for advanced technologies in clinical
diagnostics and drug discovery. This demand has led to the adoption of
cutting-edge instruments, reagents, and software platforms, which are essential
for the accurate analysis of biological samples and the development of new
therapeutic solutions. Saudi Arabia’s focus on modernizing its healthcare
infrastructure and promoting medical research has further fueled the need for
sophisticated tools and equipment.
Additionally,
the increasing prevalence of chronic diseases such as cancer, diabetes, and
cardiovascular conditions has created a surge in demand for life science tools
that enable early diagnosis and personalized treatments. The growing emphasis
on precision medicine, along with the rising number of clinical trials and
research initiatives in the country, is expected to drive the market forward.
Key Market Drivers
Growth in Healthcare Industry
The
growth of the healthcare industry is a key driver of the life science tools
market in Saudi Arabia, fueled by the country's strategic initiatives to
enhance its medical infrastructure and expand healthcare services. As part of
its Vision 2030 plan, Saudi Arabia aims to increase the number of hospitals,
improve patient care, and strengthen research capabilities, creating a demand
for advanced life science tools that support diagnostics, research, and drug
development.
One
of the primary factors contributing to this growth is the rising prevalence of
chronic diseases such as diabetes, cardiovascular disorders, and cancer. Saudi
Arabia's health law is designed to ensure equitable and accessible healthcare
for all individuals. The Ministry of Health (MoH) oversees a comprehensive
network of healthcare services that spans the entire country. Citizens receive
free healthcare in government medical facilities, guided by a new health
strategy tailored to the sector's evolving needs. In collaboration with
regional councils, the MoH assesses healthcare requirements, determining
service locations and levels based on the country's geographic and demographic
profile, as well as the prevalence of diseases in each region. These
conditions require sophisticated diagnostic tools and personalized treatments,
spurring investment in technologies like genomics, proteomics, and molecular
biology. As hospitals and research institutions seek to improve diagnostic
accuracy and treatment outcomes, the demand for advanced tools, including
next-generation sequencing (NGS) platforms and high-performance liquid
chromatography (HPLC) systems, continues to rise.
Moreover,
the government's focus on establishing Saudi Arabia as a regional hub for
healthcare and life sciences is attracting international investments and fostering
collaborations between local research institutions and global companies. This
trend is driving the adoption of cutting-edge technologies in clinical
research, biotechnology, and pharmaceutical development, further propelling the
life science tools market.
Surge in Technological Advancements
The
surge in technological advancements is a significant driver of the life science
tools market in Saudi Arabia, as the country increasingly adopts innovative
solutions to advance its research and healthcare capabilities. There are
currently 150 health tech startups operating in the Kingdom. Among them is
Cura, a locally developed app that enables users to access remote video
consultations with doctors across 34 different specialties. Similarly, the
newly launched app Labayh provides users with quick and discreet access to
qualified counselors and psychotherapists. These companies are driving
innovation, offering impactful solutions that are significantly enhancing
patient care and well-being. Rapid developments in fields such as genomics,
bioinformatics, and molecular diagnostics have created new opportunities for
life science companies to provide cutting-edge tools and technologies to meet
the growing demand for precision medicine, drug discovery, and advanced
diagnostics.
One
major technological advancement driving this market is the rise of
next-generation sequencing (NGS) platforms. These systems enable rapid and
accurate analysis of genetic information, allowing for the identification of
genetic disorders and mutations linked to diseases. As Saudi Arabia focuses on
addressing its growing burden of chronic diseases, the use of NGS and other
molecular diagnostic tools is expanding, spurring demand for related
instruments and reagents. Additionally, bioinformatics platforms, which allow for
the storage and analysis of large datasets generated from genomic studies, are
becoming essential in the country’s healthcare and research sectors.
Furthermore,
the integration of artificial intelligence (AI) and automation in laboratory
workflows is revolutionizing research and clinical practices in Saudi Arabia. The
Kingdom of Saudi Arabia is advancing the localization of manufacturing for
cutting-edge medical tools, including nanoscale drug delivery systems, RNA
interference technologies, induced pluripotent stem cells, the Human Genome
Project, biochips, gene therapy, phage therapy, and bionanotechnology. By
reducing reliance on health-related imports, this strategic move will not only
lower domestic healthcare costs but also stimulate the creation of high-paying
jobs, drive economic growth, and position Saudi Arabia as a global leader in
healthcare innovation. AI-powered systems are enhancing the efficiency of
data analysis, improving the accuracy of diagnostics, and accelerating the
discovery of new treatments. Automated laboratory tools, such as robotic liquid
handling systems and high-throughput screening platforms, are also enabling
faster and more reliable experimentation, reducing errors and streamlining
research processes.
Download Free Sample Report
Key Market Challenges
High Dependency on Imports
One
of the key challenges facing the Saudi Arabian life science tools market is its
high dependency on imports. The country relies heavily on importing advanced
instruments, reagents, and other life science tools from international
suppliers to support its healthcare, pharmaceutical, and biotechnology sectors.
This reliance poses several challenges for the market’s growth and
sustainability.
Firstly,
the high dependency on imported products often leads to increased costs, as
local buyers must account for shipping expenses, import duties, and currency
fluctuations. These factors can inflate the overall cost of acquiring advanced
life science tools, making it more difficult for smaller institutions or startups
to access the latest technologies. As a result, innovation and research may be
hindered due to financial constraints.
Secondly,
delays in international supply chains can disrupt the timely availability of
critical tools and equipment needed for research and diagnostics. These
disruptions, exacerbated by global events such as the COVID-19 pandemic,
highlight the vulnerability of Saudi Arabia’s life science market to external
factors beyond its control. Delays in receiving necessary imports can slow down
scientific progress, medical testing, and the implementation of new healthcare
technologies.
Key Market Trends
Growing Demand for Clinical
Diagnostics and Molecular Testing
The
growing demand for clinical diagnostics and molecular testing is emerging as a
significant trend in the Saudi Arabia life science tools market. This shift is
largely driven by an increasing focus on early disease detection, personalized
medicine, and precision healthcare. With the rising incidence of chronic and
infectious diseases, such as diabetes, cancer, and viral infections, there is a
greater need for advanced diagnostic techniques that offer higher accuracy and
quicker results.
Molecular
karyotyping is currently offered at only a select number of centers. The
primary molecular diagnostic facility is the Saudi Diagnostic Laboratory (SDL)
at King Faisal Specialist Hospital & Research Centre (KFSHRC), which
conducts tests for 66 single-gene disorders. The organization is in the process
of validating the “Mendeliome” assay, which employs advanced multiplexing
techniques to amplify approximately 3,000 Mendelian genes associated with human
diseases, followed by next-generation sequencing. This assay is being validated
on a cohort of 3,500 patients. Once the validation is complete, the test will
be available to all patients with suspected genetic disorders, serving as an
intermediary diagnostic tool before proceeding to whole-exome or whole-genome
sequencing.
Molecular
testing, including polymerase chain reaction (PCR) and next-generation
sequencing (NGS), has become crucial for identifying genetic mutations and
understanding disease mechanisms. These technologies enable healthcare
providers to make informed decisions about patient care, tailoring treatments
to individual genetic profiles and improving therapeutic outcomes. The adoption
of molecular diagnostics in Saudi Arabia is particularly prominent in oncology,
infectious disease testing, and genetic screening, where precision medicine
plays a pivotal role in treatment planning.
Additionally,
Saudi Arabia’s healthcare transformation under Vision 2030, which includes
initiatives to improve healthcare access and quality, has accelerated the
demand for sophisticated diagnostic tools. Hospitals, research institutions,
and clinical laboratories are increasingly investing in state-of-the-art
equipment for molecular testing to enhance diagnostic capabilities. The
government’s efforts to localize healthcare services and promote research and
innovation in life sciences have also fueled investments in molecular
diagnostics platforms.
Segmental Insights
Product Insights
Based
on Product, Cell Culture Systems & 3D Cell Culture have emerged as the fastest
growing segment in the Saudi Arabia Life Science Tools Market in 2024. One
primary factor driving the rapid growth of these segments is the surge in
pharmaceutical and biotechnology research in Saudi Arabia. With the country’s
strategic focus on improving healthcare outcomes and advancing its life
sciences sector, there is a growing demand for advanced in vitro models that
enable researchers to better understand disease mechanisms, test drug efficacy,
and screen for potential therapeutics. 3D cell culture systems, in particular,
provide a more physiologically relevant environment for cell growth, making
them indispensable in drug discovery and cancer research.
Furthermore,
the increasing prevalence of chronic diseases such as cancer, diabetes, and
neurological disorders in Saudi Arabia has created a demand for more effective
and personalized treatment options. 3D cell cultures are instrumental in this
process, as they enable researchers to mimic tumor microenvironments or other
disease-specific conditions, enhancing the development of targeted therapies
and personalized medicine approaches. This is particularly important as Saudi
Arabia’s healthcare system continues to evolve towards precision medicine,
which requires advanced tools for patient-specific treatment strategies.
Technology Insights
Based
on Technology, Genomics have emerged as the fastest growing segment in the Saudi
Arabia Life Science Tools Market during the forecast period. Saudi Arabia’s
Vision 2030 initiative prioritizes the development of advanced healthcare and
biotechnology sectors. Significant investments are being made in genomics
research, personalized medicine, and healthcare infrastructure, which directly
boosts the demand for genomics-related tools and technologies.
The
growing emphasis on precision medicine, which tailors medical treatments to
individual genetic profiles, has led to an accelerated demand for genomic
technologies. This shift is prompting healthcare providers and research
institutions to adopt advanced genomic tools for more accurate diagnostics and
treatment strategies.
Download Free Sample Report
Regional Insights
Based
on Region, Northern & Central have emerged as the dominating region in the Saudi
Arabia Life Science Tools Market in 2024. The Northern and Central regions,
particularly Riyadh, which is the capital and largest city, are home to major
research institutions, hospitals, and clinical laboratories. The concentration
of leading healthcare and educational facilities has created a high demand for
advanced life science tools and technologies, particularly in research and
diagnostic applications.
The
Central region, specifically Riyadh, is not only the political and
administrative capital but also a business hub where many multinational life
science companies have established operations or partnerships. The region's
infrastructure and logistical connectivity make it an attractive location for
companies engaged in life science tools manufacturing, distribution, and
R&D activities.
Recent Development
- In March 2024, the Public Investment Fund (PIF) launched Lifera as a national biopharma CDMO platform, driving demand for bioprocess tools and analytical systems across upstream, downstream, fill-finish, and quality control labs to support vaccine, biologics, and advanced modality localization.
- In April 2024, Lifera, fully owned by PIF, acquired SaudiBio to strengthen domestic biomanufacturing. The acquisition funded facility upgrades and technology transfer initiatives requiring advanced process equipment, analytics, and QC tools for biologics, including insulin.
- In January 2025, King Saud bin Abdulaziz University for Health Sciences announced the Life Sciences Innovation Forum 2025 in Riyadh to connect investors with biotech tool innovators and translational researchers, signaling rising demand for instruments, consumables, and enabling platforms in the Kingdom’s research hospitals.
- In June 2025, Saudi Arabia launched its first national pavilion at BIO 2025, announcing more than a dozen MoUs between Saudi health and science institutions and global biotech technology leaders to accelerate technology transfer, research tooling, and localization of advanced platforms.
- In the same month, the Ministry of Health and partners introduced a start-up accelerator with BioLabs at BIO 2025, offering Saudi start-ups access to world-class wet lab infrastructure, equipment, and mentorship, expanding early-stage access to life science tools and innovation resources.
- In January 2025, Redesign Health entered into a partnership with Sanabil Investments to establish a healthcare venture studio in Saudi Arabia. This venture studio aims to facilitate the launch and growth of startups focused on addressing critical healthcare challenges through innovative solutions. Additionally, it is expected to generate new employment and entrepreneurial opportunities within the Kingdom. Redesign Health plans to set up a local office in Saudi Arabia, supported by a dedicated team to drive its venture-building initiatives.
- In
May 2024, Bayer, a global leader in life sciences, and Huma Therapeutics
Limited ("Huma"), a prominent digital health company, announced the
launch of their innovative heart health screening tool in Saudi Arabia. This
marks the first global rollout since the Bayer Aspirin Heart Health Risk
Assessment debuted in the United States in 2023 and aligns with key objectives
of Saudi Arabia's Vision 2030 national strategy. The Bayer Aspirin Heart Health
Risk Assessment is a digital-only solution designed to quickly assess an
individual's risk of developing cardiovascular disease (CVD) over the next
decade, eliminating the need for invasive blood tests and blood pressure
measurements. The algorithm, developed by Huma, utilizes over 15 years of
longitudinal data from more than 500,000 individuals in the UK Biobank Dataset.
Clinical validation by the European Society of Cardiology demonstrated that the
Heart Health Risk Assessment showed strong predictive accuracy compared to the
standard of care.
- In
January 2024, Crown Prince Mohammed bin Salman of Saudi Arabia unveiled a
comprehensive strategy aimed at localizing vaccine production and strengthening
the nation’s healthcare sector. The initiative focuses on significantly
increasing the country’s self-sufficiency in ensuring timely access to
medicines for its citizens. A key goal is for the biotechnology sector to
contribute 3% to the non-oil GDP by 2040, generating an estimated economic
impact of USD 34.66 billion. The strategy also anticipates the creation of
numerous job opportunities. Four primary objectives are outlined, with a strong
emphasis on localizing vaccine manufacturing, expanding exports, and fostering
innovation in the field. Additionally, the strategy prioritizes advancing local
biomanufacturing capabilities and focuses on genomics, including pioneering
research, gene therapy, and plant enhancement.
Key Market Players
- Becton,
Dickinson, and Company
- Al
Zahrawi Medical Supplies LLC
- Thermo
Fisher Scientific Inc.
- Bio-Rad
Laboratories, Inc.
- Merck
Limited
|
By Product
|
By Technology
|
By Region
|
- Cell Culture Systems & 3D Cell Culture
- Liquid Chromatography
- Mass Spectrometry
- Flow Cytometry
- Cloning & Genome Engineering
- Microscopy
- Next Generation Sequencing
- PCR & qPCR
- Nucleic Acid Preparation
- Nucleic Acid Microarray
- Sanger Sequencing
- Transfection Device & Gene Delivery Technologies
- Nuclear Magnetic Resonance
- Others
|
- Genomics
- Proteomics
- Cell Biology Technology
- Lab Supplies
- Others
|
- Eastern
- Western
- Northern & Central
- Southern
|
Report Scope
In this report, the Saudi Arabia Life Science Tools
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Saudi Arabia Life Science Tools Market, By Product:
o Cell Culture Systems & 3D Cell Culture
o Liquid Chromatography
o Mass Spectrometry
o Flow Cytometry
o Cloning & Genome Engineering
o Microscopy
o Next Generation Sequencing
o PCR & qPCR
o Nucleic Acid Preparation
o Nucleic Acid Microarray
o Sanger Sequencing
o Transfection Device & Gene Delivery
Technologies
o Nuclear Magnetic Resonance
o Others
- Saudi Arabia Life Science Tools Market, By Technology:
o Genomics
o Proteomics
o Cell Biology Technology
o Lab Supplies
o Others
- Saudi Arabia Life Science Tools Market, By
Region:
o Eastern
o Western
o Northern & Central
o Southern
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Saudi
Arabia Life Science Tools Market.
Available Customizations:
Saudi Arabia Life Science Tools Market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Saudi Arabia Life
Science Tools Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]